Literature DB >> 32659400

Ginsenoside Rb1 ameliorates autophagy via the AMPK/mTOR pathway in renal tubular epithelial cells in vitro and in vivo.

Xianghua Liu1, Jinwei Chen2, Ning Sun1, Ningning Li3, Zhenqiang Zhang1, Tao Zheng4, Zhenzhen Li5.   

Abstract

Although ginsenoside Rb1 (G-Rb1) has exerted an inhibitory effect on renal fibrosis and progression of chronic kidney disease (CKD), its mechanism remains unknown. This study aims to explore the anti-fibrosis effect of G-Rb1 in unilateral ureter obstruction (UUO) mouse model and underlying mechanisms in HBSS-induced HK-2 cells. In vivo, renal function, kidney histological pathology, and autophagy-related protein molecules were assessed. Additionally, rapamycin, Deptor overexpression plasmid, Akt inhibitor, metformin, and a p38-MAPK inhibitor, as well as an ERK-MAPK inhibitor were used to evaluate the effect of AMPK/mTOR, Akt and MAPK signal pathways on the protective effect of G-Rb1 in HK-2 cells. Treatment with G-Rb1 significantly improved renal dysfunction. G-Rb1 reversed UUO-induced downregulation of p62, and upregulation of LC3 and the ratio of LC3 I/II, indicating that G-Rb1 restrained UUO-induced activation of autophagy. Furthermore, we found that treatment of HBSS-induced HK-2 cells with G-Rb1 resulted in AMPK/mTOR and ERK, p38 MAPKs signaling pathways regulated autophagy inhibition. These findings may explain, in part, the molecular mechanisms by which G-Rb1 could be applied in the treatment of patients with CKD, further suggesting that autophagy and its associated molecular signaling pathway may be new targets for the treatment of renal fibrosis and CKD.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK; Autophagy; Ginsenoside Rb1; Renal fibrosis; Tubular epithelial cells

Mesh:

Substances:

Year:  2020        PMID: 32659400     DOI: 10.1016/j.ijbiomac.2020.07.060

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  7 in total

Review 1.  Neuroprotective Mechanisms of Ginsenoside Rb1 in Central Nervous System Diseases.

Authors:  Liang Gong; Jiayi Yin; Yu Zhang; Ren Huang; Yuxuan Lou; Haojie Jiang; Liyan Sun; Jinjing Jia; Xiansi Zeng
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  Ginsenoside Rb1 Alleviates Bleomycin-Induced Pulmonary Inflammation and Fibrosis by Suppressing Central Nucleotide-Binding Oligomerization-, Leucine-Rich Repeat-, and Pyrin Domains-Containing Protein Three Inflammasome Activation and the NF-κB Pathway.

Authors:  Jingjing Liu; Guoqing Fan; Ningning Tao; Feifei Feng; Chao Meng; Tieying Sun
Journal:  Drug Des Devel Ther       Date:  2022-06-13       Impact factor: 4.319

3.  Gypenosides Attenuate Pulmonary Fibrosis by Inhibiting the AKT/mTOR/c-Myc Pathway.

Authors:  Suqing Liu; Qingqing Yang; Binbin Dong; Chunhui Qi; Tao Yang; Ming Li; Shan He; Baojun Liu; Jinfeng Wu
Journal:  Front Pharmacol       Date:  2022-01-14       Impact factor: 5.810

4.  Ginsenoside Rb1 Mitigates Escherichia coli Lipopolysaccharide-Induced Endometritis through TLR4-Mediated NF-κB Pathway.

Authors:  Aftab Shaukat; Irfan Shaukat; Shahid Ali Rajput; Rizwan Shukat; Sana Hanif; Imran Shaukat; Xinxin Zhang; Chao Chen; Xuyang Sun; Tingzhu Ye; Kaifeng Niu; Zhiqiu Yao; Shadab Shaukat; Muhammad Safdar; Mohamed Abdelrahman; Umair Riaz; Junwei Zhao; Xiaoying Gu; Liguo Yang
Journal:  Molecules       Date:  2021-11-23       Impact factor: 4.411

Review 5.  Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease.

Authors:  Miao Wang; Xin Lin; Xiaoming Yang; Yanlang Yang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

Review 6.  Autophagy in renal fibrosis: Protection or promotion?

Authors:  Rong Dai; Lei Zhang; Hua Jin; Dong Wang; Meng Cheng; Tian Sang; Chuyi Peng; Yue Li; Yiping Wang
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

7.  In Vitro and In Vivo Antifibrotic Effects of Fraxetin on Renal Interstitial Fibrosis via the ERK Signaling Pathway.

Authors:  Yi-Hsien Hsieh; Tung-Wei Hung; Yong-Syuan Chen; Yi-Ning Huang; Hui-Ling Chiou; Chu-Che Lee; Jen-Pi Tsai
Journal:  Toxins (Basel)       Date:  2021-07-09       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.